A recent article by regan et al.
(1) on tamoxifen pharmacogenetics, although conducted at a high standard in most respects, presents highly implausible CYP2D6 genotyping results that raise serious doubt about the conclusions. Determining constitutional genotypes from formalin-fixed paraffin-embedded (FFPe) tumor tissue is technically challenging, particularly with a complex gene like CYP2D6 that exhibits copy number variation and is flanked by two highly similar pseudogenes. the potential for genotyping errors attributable to allele loss in breast cancer must also be considered. one widely recognized method for quality control of genotyping data is to determine whether allele frequencies conform to hardy-Weinberg proportions. hence the genotype frequencies reported by regan et al. were tested for hardy-Weinberg equilibrium (hWe) using the Pearson χ 2 test (2).the results are presented in table 1. the probability of the reported genotypes is astronomically small (eg, the probability of the reported CYP2D6*4 allele proportions is 2. 5 (1) . to normalize the distorted allele frequencies requires different Loh adjustments for different CYP2D6 polymorphisms, which would entail highly unlikely intragenic rearrangements. I calculated that the three alleles that require the largest adjustment are CYP2D6*41 (~45% Loh), CYP2D6*4 (~32% Loh), and CYP2D6*3 (~30% Loh). In contrast, only a 15% Loh adjustment is required to bring CYP2D6*6 into hWe. CYP2D6*41 and CYP2D6*4 were the only alleles genotyped using commercial taqman assays, and both required extra cycles in the polymerase chain reaction, indicating assays operating at (or beyond) their limits. It may be that these factors contributed to the erroneous results.
the article by rae et al. (6) did not provide enough genotype data to fully evaluate whether similar methodological problems occurred. however, genotype data for the CYP2D6*4 allele in 588 breast cancer patients who were randomly assigned to the tamoxifen group [ Supplementary Figure 1 , A, available online (6)], were not in hWe (χ 2 = 18.1, P = .000021). heterozygotes are depleted and homozygotes enriched compared to the allele frequencies expected in hWe. the UGTB27*2 genotypes were in hWe. Table 2 of Regan et al.
(1) were presented in terms of the percentage of tested subjects who were homozygous for the mutant allele, heterozygous, or homozygous for the wild-type allele. By multiplying those percentages by the number of subjects successfully genotyped (also from Table 2 of Regan et al.), one can calculate the approximate number of subjects with each genotype ("Inferred genotype frequencies" in the table above). Those frequencies were used to calculate allele frequencies, which were then used to calculate "Expected genotype frequencies" using the Hardy-Weinberg equation. Finally, the probability of the reported genotype proportions from Regan et al.
(1) (converted into inferred genotype frequencies) was estimated using the χ 2 distribution as described previously by Rodriguez et al. (2). Calculations were done using an online calculator created by Rodriguez et al. (2). † P values were determined from the χ 2 distribution; they are one-sided (right-tail). Two sided P values would be double the values shown, which does not affect any of the conclusions.
Response
Pharoah et al., Nakamura et al., and Stanton have questioned the validity of two recent articles published in the Journal (1,2). they specifically question the genotyping quality in the Breast International Group (BIG) 1-98 study (1). Nakamura et al., in fact, urge the retraction of the BIG 1-98 study and reanalysis of all studies utilizing tumor DNA for genotyping. We welcome the discourse that comes with comprehensive reporting of results as a valuable part of peer review. We too are keen proponents of personalized medicine. however, we believe that adopting a new test into standard clinical care requires high levels of evidence demonstrating clinical utility. We were disappointed that the results of these two investigations did not support the hypothesis that CYP2D6 genotype was associated with the outcome of postmenopausal women with early breast cancer treated with tamoxifen. We stand firmly behind the quality of methodology of the BIG 1-98 study, the contribution of our results to the body of literature, and the value that the two investigations (1,2) together bring to informing the care of patients with breast cancer.
unfortunately, Nakamura et al. misrepresent our conclusions. We believe that CYP2D6 pharmacogenetic testing is not justified for clinical use to determine whether tamoxifen should be given to postmenopausal women nor to withhold treatment with an aromatase inhibitor. Although our results do not support the hypothesis, we did not purport to settle the controversy of whether CYP2D6 genotype is associated with the pharmacodynamics of tamoxifen, and we eagerly await the results of the Eastern Cooperative Oncology Group 3108 (Clinicaltrials.gov Identifier NCt01124695) and european CyPtAmBrut-2(Clinicaltrials.gov Identifier NCt00965939) trials.
With respect to Pharoah et al.'s question regarding replicates, we used 32 different replicates for every genotyping run; replicates were 100% concordant across the experiment. We should have referenced their investigation (3), which genotyped 3155 breast cancer patients who had received tamoxifen, and notably also concluded that CYP2D6 testing is not currently justified to direct clinical patient care.
All three letters raise the issue of deviation from hardy-Weinberg equilibrium (hWe) in the BIG 1-98 study. testing for deviation from hWe is a recommended practice for population-based genetic association studies as a possible indicator of systematic genotyping errors. this concept applies to biallelic autosomal genes, and it may not be expected nor required when examining CYP2D6 genotypes. It is well known that the CYP2D6 has germline gene deletions and duplications (4) , and these can complicate straightforward hWe testing.
For technical reasons, we were unable to assay the CYP2D6*5 allele, which is an established germline deletion of the entire gene. the result of undetected CYP2D6*5 is the misclassification of homozygous genotype for the other allele. Indeed this is a possible explanation for observed excess of homozygotes in studies such as ours and deviation from hWe.
In fact, the issue of CYP2D6 genotypes deviating from hWe has been observed in previous studies that assessed associations between CYP2D6 genotypes and outcomes in tamoxifen-treated patients (5-7). Small sample sizes have limited others from detecting statistically significant deviations from hWe (sometimes inaccurately characterized as being consistent with hWe). For example, the study by Goetz et al. (5) (in which Dr rae of this response and Dr Flockhart of the Nakamura et al. letter were coauthors), which found CYP2D6*4/*4 genotype to be associated with poorer outcomes in tamoxifen-treated patients and initiated interest in the hypothesis that CYP2D6 genotype is associated with the outcome of breast cancer patients, also deviated from hWe. Like our study, the Goetz et al. study was performed on tumor tissue. A total of 190 patients were successfully genotyped for CYP2D6*4, andCYP2D6*5 was not determined. the CYP2D6*4 genotype frequencies (CYP2D6*4/*4, n = 13 patients; CYP2D6*4/WT, n = 40 patients; WT/WT, n = 137 patients) deviate statistically significantly from hWe (continuity-corrected χ 2 = 12, P = .0006; exact P = .0006). the effect of undetected CYP2D6*5 and the statistical power to detect deviation from hWe are amplified in our study due to the sample size. If one takes the same genotype proportions reported in the Goetz et al. study (5) and scales them to the sample size of BIG 1-98, then when the sample size becomes 3800 patients, the deviation from hWe is amplified (continuity-corrected χ 2 = 268, P = 2.9e-60; exact P = 1.3e-51). therefore, when adjusted to scale, the test of deviation from hWe in the Goetz et al. study is very similar to that in BIG 1-98. Should the data from Goetz et al. and subsequent reports be retracted based on the arguments of Nakamura et al. ? We say no, given the likely and plausible explanation that undetected CYP2D6*5 invalidates hWe testing in these situations.
When using DNA extracted from formalin-fixed paraffin-embedded (FFPe) tumor samples, could hemizygous somatic deletions of CYP2D6 in the tumor cells affect CYP2D6 genotype, as suggested by
